ArticleCureus2025

Identifying Predictive Factors for Complete Skin Clearance at Week 52 by Deucravacitinib in Moderate-to-Severe Psoriasis: A Prospective Observational Study.

Yohei Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.